Literature DB >> 1896096

Disturbances of cerebral purine and pyrimidine metabolism in young children with chronic renal failure.

G P Gerrits1, L A Monnens, R A De Abreu, C H Schröder, J M Trijbels, F J Gabreëls.   

Abstract

Chronic renal failure during childhood may be associated with delayed cognitive development. From 10 children with chronic renal failure, aged 2-59 months, plasma and cerebrospinal fluid (CSF) purines and pyrimidines have been determined. A marked increase of pseudouridine and cytidine was demonstrated in CSF of 10 and 8 children, respectively. The plasma concentration of pseudouridine was increased in a varying degree to a maximal value of more than 10 times the upper limit of normal. The plasma concentration of cytidine showed only moderately elevated values. In 3 children the study of CSF and plasma was repeated 6 weeks after the start of continuous ambulatory peritoneal dialysis. The abnormal concentrations of pseudouridine and cytidine were still present in CSF and plasma. Further studies are necessary to elucidate the cause of this unknown biochemical aberration of the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1896096     DOI: 10.1159/000186442

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  6 in total

Review 1.  Physiological concentrations of purines and pyrimidines.

Authors:  T W Traut
Journal:  Mol Cell Biochem       Date:  1994-11-09       Impact factor: 3.396

2.  Cerebrospinal fluid amino acids, purines and pyrimidines as a tool in the study of metabolic brain diseases.

Authors:  G P Gerrits; L A Monnens; F J Gabreëls; R A De Abreu; A Koster; J M Trijbels
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

3.  Structure-activity relationship of a pyrimidine receptor in the rat isolated superior cervical ganglion.

Authors:  G P Connolly; P J Harrison
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

4.  Evoked potentials in children with chronic renal failure, treated conservatively or by continuous ambulatory peritoneal dialysis.

Authors:  W Hurkx; I Hulstijn-Dirkmaat; J Pasman; J Rotteveel; Y Visco; C Schröder
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714

5.  Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.

Authors:  Monika A Niewczas; Tammy L Sirich; Anna V Mathew; Jan Skupien; Robert P Mohney; James H Warram; Adam Smiles; Xiaoping Huang; Walker Walker; Jaeman Byun; Edward D Karoly; Elizabeth M Kensicki; Gerard T Berry; Joseph V Bonventre; Subramaniam Pennathur; Timothy W Meyer; Andrzej S Krolewski
Journal:  Kidney Int       Date:  2014-01-15       Impact factor: 10.612

6.  Identification of biomarkers for development of end-stage kidney disease in chronic kidney disease by metabolomic profiling.

Authors:  Tomonori Kimura; Keiko Yasuda; Ryohei Yamamoto; Tomoyoshi Soga; Hiromi Rakugi; Terumasa Hayashi; Yoshitaka Isaka
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.